Randomized, Controlled, Double-blind Clinical Trial Comparing the Efficacy and Safety of Chemoprophylaxis With Hydroxychloroquine in Patients Under Biological Treatment and / or JAK Inhibitors in the Prevention of SARS-CoV-2 Infection

Stopped * Care pressures on the investigator team during the COVID-19 pandemic. * Subsequent appearance of scientific evidence on the lack of efficacy of hydroxychloroquine in the treatment or prophylaxis of COVID-19 infection.

Conditions

• COVID 19
• Immunomediated Inflammatory Disease in Treatment With Biological Agents and / or Jak Inhibitors

Interventions

• DRUG: Hidroxicloroquina
• DRUG: Control group

Sponsor

Instituto de Investigación Marqués de Valdecilla